glp 1 glucagon like peptide Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Synthesis, secretion, and metabolism of
Description
Studies published in English with treatment duration 12 weeks and information on HbA1c changes were included
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
2022 Nov 16;13:1015045
Novo Nordisk CEO says being first in obesity created the market for competitors, as company fights to maintain GLP-1 market leadership.
Learn why it happens, when it fades, and what boosts energy
